Table 7.
Follow-up
| SAFE or Initial Examination | 3–7 da | 2 wka | 3–6 wka | 3 moa | 6 moa | |
|---|---|---|---|---|---|---|
| UDS if suspect drug facilitation | ≤96 h | |||||
| Pregnancy | X | ≥7 d | ||||
| Anogenital examination | X | Reevaluate any positive findings | Evaluate for warts; primary syphilis with dark field examination | if signs present | ||
| Wet mount if discharge present | X | X | ||||
| Gonorrhea, chlamydia, trichomonas if negative initial test and no empiric treatment | X | ≥7 d or, not initially tested | if signs present | b | ||
| Medication tolerance/adherence. Adjust medications accordingly | X | X | ||||
| ALT, AST, creatinine, complete blood count if taking PEP | X | X | ||||
| HIV combined antigen/antibody, with confirmatory test as needed | X | X (4 wk if fourth generation; 6 wk if third generation) | X | In addition, only if third generation | ||
| Hepatitis B surface antibody | X | |||||
| Hepatitis Cc | X | x | ||||
| Nontreponemal syphilis (RPR or VDRL), with confirmatory test as needed | X | X | X | X | ||
| Psychiatric well-being | X | X | X | X | X | X |
a
Time from last suspected encounter.
b
Retest sexually active women 2 wk to 3 mo after trichomonas treatment. Retest chlamydia and gonorrhea 3 mo after treatment in both genders for assessment of new infection if sexually active.
c
Hepatitis C serology may be considered, but is not substantiated by research in the circumstance of sexual assault.